CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early
Go back to CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.82 | 52 Week High | $77.12 | |||
| Open | $66.82 | 52 Week Low | $49.03 | |||
| Day High | $66.82 | P/E | 43.39 | |||
| Day Low | $66.82 | EPS | $1.54 | |||
| Volume | 7,823 | |||||
